Free access supported by contributions and sponsoring — share your knowledge or support us financially
Search / Compare / Validate Lab equipment & Methods

H9 hesc

Manufactured by WiCell
Sourced in United States, Canada, France
About the product

H9 hESCs are a well-characterized line of human embryonic stem cells. They are derived from the inner cell mass of a pre-implantation human embryo and maintain the ability to differentiate into cells of all three germ layers.

Automatically generated - may contain errors

Market Availability & Pricing

The H9 human embryonic stem cell line (WA09) is actively available through WiCell. It is included in WiCell's catalog of stem cell lines, which offers both research-grade and clinical-grade (cGMP) materials. WiCell provides the H9 cell line in various formats, including feeder-free culture platforms, to accommodate diverse research needs. Technical support is available to assist laboratories in establishing these materials.

For detailed information on pricing and ordering, researchers are encouraged to contact WiCell directly.

Need Operating Instructions, SDS, or distributor details? Just ask our AI Agent.

Is this product still available?

Get pricing insights and sourcing options

The spelling variants listed below correspond to different ways the product may be referred to in scientific literature.
These variants have been automatically detected by our extraction engine, which groups similar formulations based on semantic similarity.

Product FAQ

124 protocols using «h9 hesc»

1

Ethical Editing of Female H9 hESCs

2024
This work complies with all relevant ethical regulations and was approved by University of Michigan Institutional Review Boards (HUM00070195). All experiments carried out on edited H9 hESCs that were obtained from WiCell and are of female sex (WiCell Lot#WB0090).
+ Open protocol
+ Expand Check if the same lab product or an alternative is used in the 5 most similar protocols
2

Ethical H9 hESC Research

2024
H9 hESCs were obtained from WiCell and used under approval from the Tasmania Health and Medical Human Research Ethics Committee (#13502) and Institutional Regulatory Board (RSRB00056538) at the University of Rochester and conformed with the ethical norms and the declaration of Helsinki.
+ Open protocol
+ Expand Check if the same lab product or an alternative is used in the 5 most similar protocols
3

Differentiation of Neural Progenitor Cells

2024
Neural progenitor cell (NPC) differentiation was performed as previously described [37 ]. Dishes for hESC cultures were coated with 0.15 mg/mL growth factor reduced Matrigel (Corning Inc, 354230, Corning, NY, USA) in DMEM/F-12 (Thermo Fisher Scientific, 11320033) for 1 h at RT prior to cell seeding. H9 hESCs (WiCell, WA09, Madison, WI, USA) were seeded as colonies and maintained in mTeSR Plus (StemCell Technologies, 05825). NPC differentiation was initiated when the hESC cultures reached 90% confluence, by replacing growth medium with Knockout Serum Replacement (KSR) medium (414 mL Knockout-DMEM (Thermo Fisher Scientific, 10829018), 75 mL Knockout-serum replacement (Thermo Fisher Scientific, 10828028), 5 mL Glutamax (Thermo Fisher Scientific, 35050061), 5 mL MEM-NEAA (Thermo Fisher Scientific, 11140050), 500 µL 2-mercaptoethanol (Thermo Fisher Scientific, 21985023), 500 µL Gentamicin (Wisent Bioproducts 450-135), 10 µM SB431542 (Tocris, 1614, Bristol, UK) and 500 nM LDN-193189 (Stemgent 04-0074, Reprocell Inc, Yokohama, Kanagawa 222-0033, Japan). Differentiation medium was replaced daily on days 4 and 5 by 75:25 KSR:N2 medium (486.5 mL DMEM/F-12 (Thermo Fisher Scientific, 11320033), 5 mL 15% glucose, 5 mL N2 supplement (Thermo Fisher Scientific, 17502048), 500 µL 20 mg/mL human insulin (Wisent Bioproducts, 511-016-CM), 2.5 mL 1 M HEPES (Thermo Fisher Scientific, 15630080), 500 µL Gentamicin), on days 6 and 7 by 50:50 KSR:N2, on days 8 and 9 by 25:75 KSR:N2 and on days 10 and 11 by N2 medium containing 500 nM LDN-193189. On day 12, differentiated NPCs were treated with Y-27632 (Tocris, 1254) for 4 h, dissociated with Accutase (Stemcell Technologies, 07922) and seeded into Matrigel coated dishes containing Neural Induction Medium (NIM, 244 mL DMEM/F12, 244 mL Neurobasal medium (Thermo Fisher Scientific, 21103049), 2.5 mL N2 supplement, 5 mL B-27 Supplement (Thermo Fisher Scientific, 17504044), 2.5 mL Glutamax (Thermo Fisher Scientific, 35050061), 125 µL 20 mg/mL human insulin, 500 µL 20 µg/mL FGF2 (StemBeads, SB500, Rensselaer, NY, USA), 10 µL 1 mg/mL hEGF (Millipore Sigma E9644) and 500 µL Gentamicin) for expansion. NPCs were passaged at full confluence a minimum of one time before neuronal differentiation.
For NPC-neuronal differentiation culture dishes were coated with 0.001% Poly-L-ornithine (Millipore Sigma, P4957) at 4 °C overnight, followed by 25 µg/mL laminin (Millipore Sigma, L2020) for 2 h at room temperature. NPCs were treated with Y-27632 for 4 h, dissociated with Accutase and seeded at a density of 20,000 cells/cm2 in NIM. Neuronal differentiation was initiated when NPCs reached 70% confluence by replacing growth medium with neuronal differentiation medium (244 mL DMEM/F-12 medium, 244 mL Neurobasal medium, 2.5 mL N2 supplement, 5 mL B27 supplement, 200 µL 50 µg/ml BDNF (Peprotech, 450-02), 200 µL 50 µg/ml GDNF (Peprotech 450-10, Thermo Fisher Scientific), 250 mg dibutyryl cyclic-AMP (Millipore Sigma, D0627), 500 µL 100 M L-ascorbic acid (FujiFim Wako Chemicals, 323-44822, Osaka, Japan), and 500 µL Gentamicin). Cells were fed every 3 days for 18 days to obtain immature neuronal networks. FMF-04-159-2 was dissolved in DMSO (Fisher Scientific, BP231) and applied in cell culture medium to hESC-derived neurons for 6 days (with a replenishment of FMF-04-159-2 -containing medium after the first 3 days) and to HEK293T cells for 18 h. HEK293T cells were treated with 500 nM of FMF-04-159-2 together with 200 nM of Bafilomycin A1 (in DMSO, NEB, 54645S) or 1 µM of MG-132 (in DMSO, EMD Millipore, 474790) for 18 h to inhibit autophagy or the UPS, respectively. For protein analysis cells were washed with cold PBS, scraped, and collected in low protein binding microcentrifuge tubes (Thermo Scientific, 90410). Cells were pelleted by centrifugation at 1000 × g for 5 min at 4 °C. The supernatant was aspirated, and the cells were lysed in cold RIPA buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate; 1% NP-40, 5 mM EDTA, pH 8.0) with protease and phosphatase inhibitors. Cell lysates were incubated on ice for 20 min, with vortexing every 5 min. Lysates were centrifuged at 18,000 × g for 20 min at 4 °C to pellet cell debris. Autophagic activity was monitored by immunoblots for LC3B (Novus Biologicals, NB100-2220). Proteasome activity was monitored by immunoblots for poly-ubiquitinated proteins (anti-ubiquitin P4D1, Cell Signaling Technology, 3136).
+ Open protocol
+ Expand Check if the same lab product or an alternative is used in the 5 most similar protocols
4

Directed Differentiation of hESCs

2024
Research within this publication complies with relevant ethical regulations. Commercially sourced H9 hESCs (WiCell) were exempted by Harvard University Embryonic Stem Cell Research Oversight Committee under approval no. E00051 as human subjects research due to patient de-identification.
Protocols associated with this work can be found on protocols.io at 10.17504/protocols.io.81wgbx13nlpk/v3.
+ Open protocol
+ Expand Check if the same lab product or an alternative is used in the 5 most similar protocols
5

Derivation of Intestinal Stem Cells from hPSCs

2024
The hIOs were differentiated from H9 hESCs (WiCell Research Institute, Madison, WI, USA) and hiPSCs as described previously62 (link),65 (link). In this study, we mainly used a hiPSC line that exhibited stable maintenance, pluripotency, and a normal karyotype. hPSCs were differentiated into definitive endoderm (DE) upon treatment with 100 ng/mL activin A (R&D Systems) for 3 days in RPMI 1640 medium (Gibco) supplemented with increasing concentrations of 0%, 0.2%, or 2% fetal bovine serum (FBS; Gibco). DE cells were cultured with RPMI 1640 medium containing 2% FBS, 500 ng/mL FGF4 (Peprotech, organoEZ Cat No. ospr-007, ORGANOIDSCIENCES Co., Ltd.), 500 ng/mL WNT3A (R&D Systems) or 3 µM CHIR99021 (R&D Systems) for 4 days to promote differentiation into 3D hindgut spheroids. The spheroids were embedded in Matrigel and cultured in hIO medium composed of advanced Dulbecco’s modified Eagle’s medium (DMEM)/F-12 medium (Gibco) containing 1 × B27 (Invitrogen), 500 ng/mL R-Spondin 1 (Peprotech, organoEZ Cat. No. ospr-001, ORGANOIDSCIENCES Co., Ltd.), 100 ng/mL EGF (R&D Systems, organoEZ Cat. No. ospr-011, ORGANOIDSCIENCES Co., Ltd.) and 100 ng/mL Noggin (R&D Systems, organoEZ Cat. No. ospr-003, ORGANOIDSCIENCES Co., Ltd.). To obtain ISCs3D-hIO from hIOs, hIOs were harvested from the Matrigel dome and digested with trypsin-EDTA for at least 5 min in a 37 °C water bath. The dissociated cells were subsequently harvested and diluted in basal medium composed of advanced DMEM/F12 medium containing 1 × B27, 15 mM HEPES (Gibco), 2 mM L-glutamine (Gibco), and 1% (v/v) penicillin/streptomycin (Gibco). ISCs3D-hIO were seeded on cell culture dishes at a seeding density of 5 × 104 cells/cm2 that were coated with 1% Matrigel (Corning, Matrigel Growth Factor Reduced (GFR) Basement Membrane Matrix, LDEV-free, 10 mL, 354230, Lot number: 2271003 J, 2319004) for one hour or XF-DISC. ISCs3D-hIO were cultured in basal media supplemented with 200 ng/mL R-Spondin 1, 100 ng/mL EGF, 100 ng/mL Noggin, 10 nM [Leu15]-Gastrin 1 (Sigma‒Aldrich), 100 ng/m WNT3A, 500 nM A-83-01 (Tocris), 10 μM SB202190 (Sigma‒Aldrich), 2.5 μM prostaglandin E2 (PGE2) (Sigma‒Aldrich), 1 mM N-acetylcysteine (Sigma‒Aldrich), and 10 mM nicotinamide (Sigma‒Aldrich) at 37 °C in a humidified 5% CO2 incubator. First, 1 μM Jagged-1 (AnaSpec Inc.) and 2.5 μM Y-27632 (Tocris) were added to the culture medium only after the cells were seeded on the culture dish. The culture media was replaced every 2 days. ISCs were dissociated with TrypLE Express solution (Gibco) for 10 to 15 min at 37 °C and passaged every 7 to 10 days.
+ Open protocol
+ Expand Check if the same lab product or an alternative is used in the 5 most similar protocols

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!

🧪 Need help with an experiment or choosing lab equipment?
I search the PubCompare platform for you—tapping into 40+ million protocols to bring you relevant answers from scientific literature and vendor data.
1. Find protocols
2. Find best products for an experiment
3. Validate product use from papers
4. Check Product Compatibility
5. Ask a technical question
Want to copy this response? Upgrade to Premium to unlock copy/paste and export options.